Key result
Sacubitril/valsartan shows potential benefit for treating cancer therapy-related cardiac dysfunction based on small observational studies, but large-scale prospective trials are needed.
Why the study?
Cardiotoxicity is a severe complication of cancer therapies, but there is a lack of well-established evidence regarding the efficacy and safety of sacubitril/valsartan for preventing and treating cancer therapy-related cardiac dysfunction.
Does sacubitril/valsartan improve outcomes in patients with cancer therapy-related cardiac dysfunction?
Does sacubitril/valsartan improve outcomes in patients with cancer therapy-related cardiac dysfunction?
This review highlights the potential of sacubitril/valsartan for treating cancer therapy-related cardiac dysfunction, emphasizing the need for large-scale prospective trials.
Should not yet change practice for cancer therapy-related cardiac dysfunction; leaves open potential benefit pending large prospective trials.
Cardiotoxicity is the most dramatic complications of cancer therapies, leading to halt in potentially life-saving anti-tumor treatment regimens and a poor survival prognosis in a non-negligible percentage of patients. Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of the cancer therapy–related cardiac dysfunction (CTRCD), while their roles in the prevention of cardiotoxicity are unclear. Sacubitril/valsartan was advantageous over ACEI in heart failure patients for further reduction of cardiovascular death or heart failure re-hospitalization. However, there is short of well-established testimony of its efficacy and safety in the prevention and treatment of CTRCD in the cardio-oncology setting. Although some small observational studies found a good performance of sacubitril/valsartan in patients with CTRCD, large-scale prospective clinical studies are required to confirm its excellent results. In this paper, we review the potential benefit of sacubitril/valsartan in human subjects with CTRCD.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2022) conducted a review in Cancer therapy-related cardiac dysfunction (CTRCD). Sacubitril/valsartan was evaluated. Sacubitril/valsartan shows potential benefit for treating cancer therapy-related cardiac dysfunction based on small observational studies, but large-scale prospective trials are needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: